Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market
May 05, 2023 16:06 ET
|
Mereo BioPharma Group plc
LONDON, May 05, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced...
Mereo BioPharma to Participate in Fireside Chat at the 22nd Annual Needham Healthcare Conference
April 13, 2023 08:00 ET
|
Mereo BioPharma Group plc
LONDON, April 13, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced...
Mereo BioPharma Reports Full Year 2022 Financial Results and Recent Highlights
March 28, 2023 16:30 ET
|
Mereo BioPharma Group plc
LONDON, March 28, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced...
Mereo BioPharma Provides Regulatory Updates on Alvelestat for the Treatment of Alpha-1-Antitrypsin Deficiency-Associated Lung Disease
March 21, 2023 06:30 ET
|
Mereo BioPharma Group plc
Clear path forward with proposed single Phase 3 study evaluating alvelestat at the 240 mg dose level versus placebo at 12-18 months for potential full approval in both the U.S. and EU No additional...
Mereo BioPharma to Participate in Fireside Chat at the SVB Securities Global Biopharma Conference
February 08, 2023 07:00 ET
|
Mereo BioPharma Group plc
LONDON, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today...
Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference
November 08, 2022 07:00 ET
|
Mereo BioPharma Group plc
LONDON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today...
Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency
November 02, 2022 16:01 ET
|
Mereo BioPharma Group plc
LONDON, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases,...
Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management
October 28, 2022 07:00 ET
|
Mereo BioPharma Group plc
Mereo to Appoint Four New Directors to its Board of Directors Rubric has Withdrawn its General Meeting Requisition Notice and Related Proposals; Agrees to Standstill Provision Through Mereo’s 2024...
Mereo BioPharma to Host Alvelestat R&D Update Call on October 31, 2022
October 24, 2022 16:30 ET
|
Mereo BioPharma Group plc
LONDON, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or “the Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology,...
Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting
October 21, 2022 07:00 ET
|
Mereo BioPharma Group plc
Reiterates Quality and Composition of Mereo’s Significantly Refreshed Board, which has the Right Skills and Experience to Guide Mereo’s Strategy and Maximize Shareholder Value Details Rubric’s...